Chronic Prostatitis: Approaches for Best Management by Lee, Kyung Seop & Choi, Jae Duck
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2012 69 Korean J Urol 2012;53:69-77
www.kjurology.org
http://dx.doi.org/10.4111/kju.2012.53.2.69
Review Article
Chronic Prostatitis: Approaches for Best Management
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Prostatitis is a prevalent condition that encompasses a large array of clinical symptoms 
with significant impacts on men’s life. The diagnosis and treatment of this disorder pres-
ents numerous challenges for urologists, most notably, a lack of specific and effective 
diagnostic methods. Chronic bacterial prostatitis is successfully treated with appro-
priate antibiotics that penetrate the prostate and kill the causative organisms. 
Prostatitis category III (chronic pelvic pain syndrome) is common, very bothersome, 
and enigmatic. Symptoms are usually prolonged and, generally speaking, treatment 
results are unsatisfactory. During the last decade, research has focused on the distress 
caused by the condition, but although our knowledge has certainly increased, there 
have been no real breakthroughs; controversies and many unanswered questions 
remain. Furthermore, the optimal management of category III prostatitis is not known. 
Conventional prolonged courses of antibiotic therapy have not proven to be efficacious. 
Novel therapies providing some evidence for efficacy include alpha-blocker, anti-in-
flammatory phytotherapy, physiotherapy, neuroleptics, and others, each offering ther-
apeutic mechanisms. A stepwise approach involving multimodal therapy is often suc-
cessful for treating patients. The UPOINT technique has been used to clinically pheno-
type these patients and drive the appropriate selection of multimodal therapy. 
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INTRODUCTION
Chronic prostatitis (CP) is one of the most prevalent con-
ditions in urology and represents an important interna-
tional health problem [1]. The prevalence of prostatitis is 
approximately 5 to 9% in the general male population. 
Prostatitis accounts for 25% of all visits to urologists, and 
up to 15 to 25% of visits to urology clinics in Korea [2]. Men 
diagnosed with CP experience impairment in both mental 
and physical domains of health-related quality of life as 
measured through validated questionnaires [3]. The wide 
scope of recommended treatments for CP indicates both the 
general uncertainty surrounding the root causes of the con-
dition and how to appropriately diagnose and treat it. 
Unlike benign prostatic hyperplasia (BPH) and prostate 
cancer, which are predominantly diseases of older men, 
prostatitis affects men of all ages, especially the middle age 
group. Although category I prostatitis (acute bacterial 
prostatitis) is relatively straightforward to diagnose by ob-
serving a tender prostate on rectal examination with sys-
temic illness (fevers, chills, dysuria) and cytokine release 
syndrome, it accounts for only approximately 5% of pa-
tients with prostatitis (National Institutes of Health [NIH] 
classification). CP is much more common and more difficult 
to diagnose and treat. Of the types of CP, chronic bacterial 
prostatitis (CBP) is rare, accounting for only 5% of such pa-
tients [4]. More than 90% of cases of CP are not associated 
with a significant bacteriuria, a condition referred to as 
chronic pelvic pain syndrome (CPPS). Cases of CPPS are 
further subdivided by the presence of inflammation in the 
extraprostatic secretions or semen (category IIIa) or the ab-
sence of it (category IIIb). Many hypotheses have been sug-
gested for the etiology of CPPS, including infection, in-
flammation, uric acid level, autoimmunity, and neuro-
muscular spasm. Therapies aimed at these specific etiol-
ogies have met with varied success, a result that may reflect 
the multifactorial nature of the syndrome. This review pro-
vides an overview of the current appropriate practice for Korean J Urol 2012;53:69-77
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treating men diagnosed with CP.
DEGREE OF CONFUSION AND FRUSTRATION 
FOR CP/CPPS
CP is a condition generally acknowledged to be associated 
with great confusion and frustration for patients and treat-
ing physicians alike. In Canada, physicians reported expe-
riencing significantly more frustration in treating prosta-
titis than they did in treating patients with BPH and pros-
tate cancer and they perceived that prostatitis affected pa-
tients’ quality of life more significantly than did BPH and 
almost as significantly as prostate cancer [5]. The degree 
of frustration for physicians in dealing with prostatitis has 
been driven primarily by a lack of confidence and comfort 
in their ability to accurately diagnose and subsequently ra-
tionalize treatment. In Japan, more than half of urologists 
(52.2%; 384/735) felt pessimistic about treating patients 
with CP/CPPS [6]. The reasons for this included incon-
sistent reporting of symptoms by patients (78.1%; 300/ 
384), lack of confidence in the treatment (60.4%; 232/384), 
and lack of confidence in their diagnosis (32%; 123/384). 
These studies support the common frustration experi-
enced by physicians in diagnosing and treating this 
disease. The prime causes of the difficulty may be the poorly 
characterized etiology of CP, the absence of definitive diag-
nostic tests, and the absence of effective therapies, the sum 
of which result in physicians feeling pessimistic and lack-
ing confidence in their diagnosis and treatment strategy 
[7].
ETIOLOGY AND PATHOGENESIS
1. Chronic bacterial prostatitis
Of patients diagnosed with prostatitis syndrome, 5 to 10% 
are suffering from chronic bacterial prostatitis CBP [4]. 
This condition is often triggered by an infection of the uri-
nary tract. The pathogen spectrum includes that of com-
plex urinary tract infections, with gram-negative and 
gram-positive bacteria, although the latter often occur only 
transiently. Animal experiments have shown that chronic 
infection leads to the formation of a biofilm in the prostatic 
acini, leading to pathogens forming colonies with enhanced 
growth conditions [8].
2. CP and CPPS
Uncertainty exists in the etiology of the majority of CP cas-
es and the etiology of CP syndromes is controversial, partic-
ularly when positive cultures for established uropathogens 
are lacking. It is evident from a previous study that in-
fectious causes are detected in only 8% of patients; the ma-
jority of cases appear to suffer from either nonbacterial 
prostatitis or prostatodynia (NIH category III: CP/CPPS) 
[9]. This is likely a reason that urologists in the Nether-
lands (40%), Wisconsin (59%), and China (64.6%) consider 
nonbacterial factors to be most important in the etiology 
of the syndrome [10-12]. However, Dutch general practi-
tioners (63%) and primary care physicians (78%) in Wis-
consin tended to implicate bacterial infection as the most 
important cause [10,11]. Recently, molecular biological re-
search has created exciting new possibilities for discover-
ing the root causes of this enigmatic disease. Some evidence 
suggests that hidden bacterial infection of the prostate is 
a possible etiology [13]. In Korea, about half (52%) of partic-
ipating urologists pointed to hidden bacterial infection as 
the etiology of chronic abacterial prostatitis [14]. This re-
sult demonstrates that Korean urologists regard bacterial 
infection as an important cause of CP. Psychological factors 
may also be important in the etiology of CP, and patients 
may benefit from psychotherapy and behavioral support 
[15]. In the Netherlands, about 40% of general practi-
tioners and 65% of urologists envisaged a psychosomatic 
component to this syndrome [10]. Similarly, 40.8% of Chin-
ese urologists considered psychosomatic factors as a cause 
of CP [12]. Established diagnostic tests for patients diag-
nosed with CP are typically unrewarding and successful 
therapeutic treatment is difficult [10]. This situation may 
lead to the belief of physicians that a psychosomatic compo-
nent exists in many patients.
There is evidence to suggest that CP/CPPS is initiated 
by inflammation provoked by an initiator stimulus within 
the prostate gland, which in susceptible individuals results 
in peripheral nervous system sensitization in the prostate 
and surrounding areas [16]. This condition may result in 
neuropathic pain with allodynia and hyperalgesia and may 
explain the adequacy of treatments directed at prostatic in-
flammation in men with long-standing symptoms [17]. 
However, the initiator stimuli have not yet been precisely 
defined, and it is likely that more than one factor triggers 
CP/CPPS [16].
It has been proposed that intraprostatic reflux of urine 
(especially urate) results in chemical injury to the epi-
thelium that initiates an immunologic reaction, a possible 
starting point for chronic inflammation [18,19]. Neverthe-
less, this hypothesis has not been followed up with con-
clusive studies and therapeutic achievements. In chronic 
fibromyalgia, extensive recent researches has provided 
evidence of a lowered pain threshold determined by the in-
dividual’s genetic characteristics [20,21]. Those predispo-
sed patients may have the condition ‘triggered’ by ‘stre-
ssors’ such as infection, physical trauma, or severe psycho-
logical trauma [21]. These abnormalities may be present 
at several levels of pain: processing systems as well as psy-
chological pathways, both domains being influenced by 
specific genetic variants [22]. The possibility of impair-
ment of anti-nociceptive pathways due to deficiencies in 
the serotonergic/noradrenergic pathways, such as those 
present in chronic fibromyalgia, is a consideration that 
warrants exploration, as it would have immediate ther-
apeutic implications for successfully treating CP/CPPS 
[21]. The existence of an altered autonomic nervous system 
response in men with CP/CPPS has also recently been re-
ported [23].Korean J Urol 2012;53:69-77
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DIAGNOSIS
There is no gold standard for diagnostic testing for 
CP/CPPS [24]. A history of chronic pelvic pain in a man 
without documented infections supports the diagnosis of 
CP/CPPS. A history of recurrent or a recent urinary tract 
infection should raise suspicion for the existence of CBP. 
The evaluation of a patient presenting with symptoms of 
prostatitis must begin with a thorough medical history and 
physical examination. A complete inventory of other medi-
cal problems should be obtained to include any neurologic 
disorders.
1. Recommended evaluation
Standardized questionnaires may be useful in the evalua-
tion of prostatitis and have been classified as recommended 
diagnostic tools. Many patients present a constellation of 
symptoms that may be difficult to assess objectively. 
Therefore, through literature review, peer groups, expert 
opinions, and patient testing, a symptom assessment ques-
tionnaire was developed by the NIH [25]. The NIH chronic 
prostatitis symptom index (NIH-CPSI) consists of nine 
parts that outline three major areas of prostatitis: pain, uri-
nary symptoms, and quality of life [26]. Scores can be calcu-
lated on a summative scale or can be used independently 
to individually evaluate the three target areas. The symp-
tom index is useful to longitudinally follow the patient in 
order to monitor changes in a standardized fashion [25]. 
However, this index has limitations in use as the sole diag-
nostic tool. Recent data have indicated that the NIH-CPSI 
is more useful in evaluating the severity of a patient’s cur-
rent symptoms after a diagnosis has been established than 
in assessing the presence or absence of prostatitis [27]. 
Nonetheless, the NIH-CPSI remains an important tool for 
clinicians and researchers. Depression and psychosocial 
symptoms are concentrated in patients with CP/CPPS and 
must be addressed in tandem with physical symptoms [28]. 
Thus, cooperation with a psychologist or a physician 
trained in psychosomatic medicine is helpful. Laboratory 
and simple office tests can provide useful information when 
evaluating the patient with symptoms of prostatitis. 
Several additional tests are recommended by the NIH con-
sensus panel in the evaluation. A postvoid residual urine 
measurement provides useful information to determine 
whether a patient has incomplete bladder emptying. 
Urinary retention can be a causative factor in recurrent 
urinary tract infections and storage symptoms. Urine flow 
rates provide insight into a patient’s overall voiding status. 
Low maximum flow rates suggest bladder outlet obstruc-
tion or decreased detrusor contractility. Urine cytology is 
a simple test that can provide insight into possible ur-
othelial malignancy, which can cause irritative or ob-
structive voiding symptoms. Textbooks advise the use of 
the Meares-Stamey four-glass test, also known as a quanti-
tative prostatic localization study. Because of the time-con-
suming technique of the four-glass test and the impossi-
bility of establishing this technique in many andrology lab-
oratories, Nickel et al. [29] conducted a study to evaluate 
a simpler screening test, the two-glass test. They compared 
it with the four-glass test for the initial evaluation of men 
with a clinical diagnosis of CP/CPPS. The two-glass test 
showed strong concordance with the four-glass test and is 
suggested to be a reasonable alternative when extrapro-
static secretions are not obtained. The four-glass or 
two-glass test and the ejaculate test can be used to dis-
tinguish between inflammatory and noninflammatory 
forms of the condition [30]. Unfortunately, the results of the 
two- or four-glass tests are often neither diagnostic for pros-
tatitis nor useful in directing treatments. Recent reports 
suggest that there may be little correlation between pyuria 
and symptom manifestations [31]. A diagnostic algorithm 
that provides a practical approach to the workup of the ma-
jority of men presenting with CP/CPPS is shown in Fig. 1.
2. Optional evaluation
The complex conditions surrounding CP/CPPS often re-
quire multiple diagnostic studies to guide practitioners to-
ward therapeutic options. A urethral swab can be per-
formed for patients presenting with dysuria or localized 
pain to the urethra or penis or patients with a history of sex-
ually transmitted diseases or unprotected intercourse [25]. 
Urodynamics offers valuable information on patients with 
predominantly voiding symptoms. It can be used to supple-
ment the office evaluations of uroflow and postvoid re-
sidual urine. Urodynamics or videourodynamics help to de-
tect any prostatic obstruction, primary bladder neck ob-
struction, and detrusor-sphincter dyssynergia. These con-
ditions, which are accompanied by numerous effective 
treatment options as compared with prostatitis, may con-
tribute to or cause the pelvic pain and lower urinary tract 
symptoms experienced by the patient [25]. In 1994, Kaplan 
et al. [32] reported a series of 34 patients with refractory 
CP who underwent urodynamic evaluation. Evidence of 
bladder outlet obstruction at the vesical neck was observed 
in 31 of the 34 patients, and all but one of these patients 
showed significant improvement of symptoms after tran-
surethral incision of the bladder neck. Furthermore, in a 
second series, patients diagnosed with CP were found to 
have detrusor-sphincter dyssynergia [33]. Cystoscopy is 
also being used as an additional method of evaluation of 
CP/CPPS patients or as an adjunct to urodynamics. 
Cystoscopy should be performed in any patient with a his-
tory of hematuria or abnormal cytology. Patients with irri-
tative or obstructive symptoms may warrant cystoscopy, 
because malignancy can act as a causative agent for that 
symptomatology [25]. 
3. Semen culture
The efficacy of semen culture in the diagnosis and evalua-
tion of CBP remains unclear. A comprehensive survey de-
scribed the study results of 40 men with CBP (NIH category 
II) due to Escherichia coli infection and their subsequent 
treatment by fluoroquinolone therapy [34]. In these pa-
tients, semen cultures demonstrated significant bacter-Korean J Urol 2012;53:69-77
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FIG. 1. A suggested diagnostic algorithm for the evaluation of patients presenting with chronic prostatitis/chronic pelvic pain 
syndrome (CP/CPPS). UTIs, urinary tract infections; TRUS, transrectal ultrasonography; CT, computed tomography; MRI, magnetic 
resonance imaging; DRE, digital rectal examination; PSA, prostate-specific antigen.
iospermia (＞10
3 ml
-1) in 21 of 40 men before treatment. On 
the basis of this limited evidence, semen cultures were 
shown to identify significant bacteriospermia in only about 
50% of semen specimens from men with CBP; therefore, 
ejaculate culture is not recommended as a first line of diag-
nostic evaluation in men with suspected CBP [35]. Further 
comparative investigations will be necessary to determine 
whether ejaculate analysis may provide useful diagnostic 
information for the diagnosis of CBP.
4. Transrectal ultrasound in CP/CPPS
Imaging studies using Doppler ultrasonography have 
shown CP/CPPS to be associated with significantly in-
creased prostatic blood flow [36]. Transrectal ultrasound 
(TRUS) can also identify seminal vesicle or ejaculatory 
duct abnormalities. This imaging technique may be useful 
in evaluating patients with ejaculatory pain or hema-
tospermia [27]. However, the clinical significance of this 
finding must be further evaluated before this method can 
be used as a diagnostic tool. 
5. Serum prostate-specific antigen and CP/CPPS
In one study addressing this issue, a statistically sig-
nificant elevation of serum prostate-specific antigen 
(s-PSA) was registered [37]. However, the increase was mi-
nute and s-PSA should not be interpreted to be a useful ad-
junct for diagnosis of CP/CPPS [38]. The flip side of this coin 
is that, if s-PSA is elevated in a man with CP/CPPS symp-
toms, the patient should be evaluated for prostate cancer 
and CBP [37].
6. Hypothetical heterogeneous clinical phenotypes in 
chronic prostatitis syndromes
Patients with acute bacterial prostatitis are similar in both 
presentation of symptoms and response to therapy. In con-
trast, a single treatment fitting all patients diagnosed with 
CP does not succeed in clinical practice. It has become in-
creasingly clear that patients with CBP and CPPS are not 
a homogeneous group with identical etiologic mechanisms, 
but rather are a heterogeneous group of individual patients 
with widely differing clinical symptoms including genito-
urinary pain, voiding symptoms, or psychosexual pro-Korean J Urol 2012;53:69-77
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TABLE 1. Upoint clinical phenotyping strategy for patients presenting with urologic chronic pelvic pain syndrome
Upoint domain Clinical criteria Possible therapy
Urinary
Psychosocial
Organ specific
Infection
Neurologic/systemic
Tenderness
Bothersome urgency, frequency, and/or nocturia
Increased postvoid residual urine
Dysuria
Depression, maladaptive coping
Social dysfunction, stress, anxiety
Specific prostate tenderness
Leukocytosis in prostate specimens
Hematospermia
Extensive prostate calcification
Lower urinary tract obstruction
Exclude patients with clinical category I or II prostatitis
Gram-negative bacilli or enterococci in prostate-specific 
specimens
History of previous resolution with antibiotics 
Pain beyond abdomen and pelvis
Associated medical conditions such as irritable bowel 
syndrome, fibromyalgia, etc
Palpable tenderness, painful spasm or trigger points in 
pelvis or abdomen
Diet modification
Alpha-blockers
Pyridium
Anticholinergic agents
Cognitive behavioral therapy, counseling
Antidepressants, anti-anxiolytics
Quercetin
Alpha-blockers
Prostate massage
Surgery 
Antibiotics
Gabapentinoids
Amitriptyline
Neuromodulation
Physiotherapy
Muscle relaxants
Exercises
blems. Therefore, a single panacea to this challenging clin-
ical entity will likely not be found soon. Rather, the chal-
lenge is to identify which subgroup of patients will respond 
best to a particular therapy. A clinically practical pheno-
typing classification system for patients diagnosed with 
urologic chronic pelvic pain syndromes (UCPPS) has re-
cently been proposed [39]. UPOINT is a six-point clinical 
classification system that categorizes the phenotype of pa-
tients with UCPPS (which includes the CPSs) into one or 
more of six clinically identifiable domains as follows: uri-
nary, psychosocial, organ-specific, infection, neuro-
logic/systemic, and tenderness (muscle). A physician can 
easily and quickly categorize patients into one or more 
UPOINT domains and propose an individually designed 
therapeutic plan that specifically addresses the clinical 
phenotypes identified. Most patients will be categorized 
with more than one UPOINT domain and will require mul-
timodal therapy. This concept is outlined in Table 1.
TREATMENT 
1. CBP
Fluoroquinolones penetrate relatively well into the pros-
tate and are therefore the therapy of choice for CBP with 
a typical administration duration of 4 weeks. If the patho-
gen is resistant to fluoroquinolones, therapy with co-
trimoxazole for 3 months is recommended [35]. For re-
current CBP, each episode can either be treated with anti-
biotics or long-term antibiotic prophylaxis can be adminis-
trated for a duration of at least 6 months. Surgical proce-
dures such as transurethral resection of the prostate and 
radical prostatectomy are regarded as therapies of last re-
sort or as therapies for concomitant obstruction [35,40]. 
2. Chronic pelvic pain syndrome
Because functional obstruction may cause CPPS, therapy 
using alpha-receptor blockers may be of significant benefit. 
The combination of an alpha-adrenergic blocker and anti-
biotic therapy was shown to be more efficacious than anti-
biotics alone [41]. Positive results from RCTs of al-
pha-blockers, e.g., terazosin [42], alfuzosin [43], doxazosin 
[44], and tamsulosin [45], have led to a widespread use of 
alpha-blocker in the treatment of CPPS over the past years. 
The effects of alpha-blocker may include improved outflow 
performance by blocking the alpha-receptors of the bladder 
neck and prostate and by direct action on alpha-1A/D-re-
ceptors in the CNS [36]. In contrast, a meta-analysis of nine 
trials (n=734) could not show beneficial effect on pain [46]. 
Moreover, a more recent adequately powered, large, place-
bo-controlled randomized trial of 12-week treatment with 
alfuzosin failed to show any significant difference in the 
outcome measures with the exception of the Male Sexual 
Health Questionnaire score [47]. Overall, the use of al-
pha-blockers for the treatment of CPPS can no more be rec-
ommended and should probably be restricted to patients 
with proven bladder outlet obstruction. Therefore, it is rea-
sonable to use alpha-blockers for men with lower urinary 
tract symptoms as the predominant symptom complaint, 
especially in combination with antimicrobials. Muscle re-
laxants may be used if there is evidence of functional abnor-
malities in the pelvic floor muscle. Intraprostatic injection 
of botulinum toxin A is currently being investigated in 
these patients [48] and may offer a future therapeutic 
approach. Another pathogenetic hypothesis is that chronic Korean J Urol 2012;53:69-77
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FIG. 2. A suggested therapeutic algori-
thm for the treatment of patients pre-
senting with chronic prostatitis/chro-
nic pelvic pain syndrome (CP/CPPS). 
TUMT, transurethral microwave ther-
motherapy. *Amitriptyline, gabapen-
tin, biofeedback, massage therapy, 
acupuncture, neurostimulation.
bacterial infection is difficult to detect and cannot be 
cultured. For this reason, it is justifiable to treat CP/CPPS 
IIIa patients with fluoroquinolones if they have not been 
previously exposed to antibiotics, just as with CBP patients 
[35]. Nonsteroidal anti-inflammatory drugs (NSAIDs) re-
duce prostaglandin synthesis by inhibiting the enzyme cy-
clooxygenase, leading to a favorable effect on prostatic in-
flammation [49]. For this reason, patients with dominantly 
pain-related symptoms may be given NSAIDs. A random-
ized, placebo-controlled trial of pentosan polysulfate 
(Elmiron, Alza Pharmaceuticals, Mountain View, CA, 
USA) in the treatment of CPPS demonstrated a slightly 
greater improvement in symptoms over placebo after 16 
weeks, but the difference was not statistically significant 
[50]. Some herbal medicines act in a similar manner and 
could possibly be used, although they have not yet been sub-
jected to adequate clinical studies [35]. Analgesics with 
other modes of action (e.g., CNS) are indicated for intense 
pain. Anticholinergic drugs may be used for symptomatic 
treatment of patients with dominant micturition prob-
lems, including urinary urgency linked to irritable 
bladder. If a patient exhibits the symptoms of CP/CPPS, 
but without bacterial or inflammatory findings, the clinical 
picture is often classified as psychosomatic. The diagnosis 
of a somatoform disorder must be carefully considered in 
the context of other possible diagnoses and in close coopera-
tion with a urologist. In such cases, it is particularly im-
portant to define accompanying depressive symptoms, and 
these must be diagnosed and treated separately from the 
actual prostatitis symptoms. Sexual dysfunction problems 
with a partner are frequently accompanied by significant 
consequences to the relationship [51]. Physical options in-
clude repetitive prostate massage or methods to apply en-
ergy to the prostate. There is inadequate evidence support-
ing the efficacy of these approaches and they remain 
controversial. If anatomical manifestations such as cysts 
in the prostate are observed, and these cause infravesical 
obstruction, surgical procedures should be performed to re-
move the obstruction.
Neuromuscular and neuroleptic treatments have been 
observed to beneficially alter nervous system conditions 
found in chronic pain syndrome. Therefore, therapies de-
signed to improve relaxation and encourage proper use of 
the pelvic floor muscle are expected to provide symptomatic 
improvement. Although no large, published clinical trials 
exist, preliminary evidence suggests potential efficacy in 
the use of biofeedback and bladder retraining in alleviating 
symptoms [52]. When trigger-point massage was com-
bined with relaxation therapy in an uncontrolled study, 
72% of patients reported improvement [53]. Amitriptyline 
can be effective for the treatment of pain from chronic mus-
cle spasm and it has been found to be helpful in the manage-
ment of CPPS [54]. A suggested treatment algorithm based 
on these assessments is presented in Fig. 2.
3. Discussion of novel treatment in category III prostatitis
Combination therapy has been suggested as a method to 
utilize synergism between classes of drugs and appears to 
be superior to monotherapy in the treatment of CP/CPPS 
[55,56]. A rational framework is required to guide this 
therapy. UPOINT can be used to classify patients with uro-
logic chronic pelvic pain and subsequently direct appro-
priate therapy [57]. A recently completed, prospective 
study of 100 CP/CPPS patients treated with multimodal Korean J Urol 2012;53:69-77
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therapy offered specific therapies associated with each pos-
itive UPOINT domain (e.g., urinary, alpha-blocker or anti-
muscarinic; psychosocial, stress reduction/psychological 
support; organ-specific, quercetin; infection, antibiotic; 
neurologic/systemic, amitriptyline or pregabalin; tender-
ness, pelvic floor physical therapy) [58]. With a minimum 
follow-up duration of 6 months and an average follow-up 
of 50 weeks, 84 patients reached the primary endpoint of 
a six-point or greater improvement in total CPSI. Fifty-one 
patients had a 50% or greater improvement in total CPSI, 
whereas 84 patients demonstrated 25% or more improve-
ment. All patients’ CPSI subscores significantly improved 
from baseline. The improvement seen in all groups was not 
due to regression to the mean for the more symptomatic pa-
tients, because the number of UPOINT domains did not 
correlate with the drop in CPSI (Spearman r=0.034; 
p=0.74). There was no correlation between the drop in CPSI 
and the difference between the number of UPOINT do-
mains and the number of therapies (p=0.63). Although this 
was not a placebo-controlled study, the incidence and mag-
nitude of improvement was significantly higher than re-
ported in prior large or multicenter studies of comparable 
duration.  
CONCLUSIONS
CP remains a controversial condition with little agreement 
regarding the best treatment option. No formal evaluation 
standard exists, and clinicians should tailor diagnostic 
studies to a patient’s specific symptoms and complaints 
while maintaining awareness that CP/ CPPS remains a di-
agnosis of exclusion. The difficulty in finding efficacious 
treatment for any given patient likely lies in the heteroge-
neous nature of both the manifestation of causative con-
ditions and the patient responses. The UPOINT system 
has attempted to help to define the different symptomatic 
domains in this difficult-to-treat condition, allowing physi-
cians to target appropriate therapies and allowing re-
searchers to narrow study populations in an attempt to dis-
cover a worthwhile treatment. It is important for the pa-
tient that he be informed as soon as possible about his con-
dition, including the necessary diagnostic steps and possi-
ble therapies, and that a specific plan for his diagnosis and 
treatment be established. This is the best way to develop 
trust between doctor and patient. This trust is critically im-
portant because, for any given patient, it often happens 
that several unsuccessful attempts are made at treatment 
before an acceptable result is reached.
CONFLICTS OF INTEREST
The authors have nothing to disclose.
REFERENCES
1. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemio-
logy of prostatitis: new evidence for a world-wide problem. World 
J Urol 2003;21:70-4.
2. Yoo YN. Prostatitis. Korean J Urol 1994;35:575-85.
3. McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, 
Santanna J, Landis JR, et al. Quality of life is impaired in men 
with chronic prostatitis: the Chronic Prostatitis Collaborative 
Research Network. J Gen Intern Med 2001;16:656-62.
4. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostati-
tis-like symptoms in a population based study using the National 
Institutes of Health chronic prostatitis symptom index. J Urol 
2001;165:842-5.
5. Nickel JC, Nigro M, Valiquette L, Anderson P, Patrick A, 
Mahoney J, et al. Diagnosis and treatment of prostatitis in 
Canada. Urology 1998;52:797-802.
6. Kiyota H, Onodera S, Ohishi Y, Tsukamoto T, Matsumoto T. 
Questionnaire survey of Japanese urologists concerning the diag-
nosis and treatment of chronic prostatitis and chronic pelvic pain 
syndrome. Int J Urol 2003;10:636-42.
7. Pontari MA, Joyce GF, Wise M, McNaughton-Collins M. Prosta-
titis. J Urol 2007;177:2050-7.
8. Nickel JC, Olson ME, Costerton JW. Rat model of experimental 
bacterial prostatitis. Infection 1991;19(Suppl 3):S126-30.
9. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, 
Litwin MS, et al. Demographic and clinical characteristics of men 
with chronic prostatitis: the national institutes of health chronic 
prostatitis cohort study. J Urol 2002;168:593-8.
10. de la Rosette JJ, Hubregtse MR, Karthaus HF, Debruyne FM. 
Results of a questionnaire among Dutch urologists and general 
practitioners concerning diagnostics and treatment of patients 
with prostatitis syndromes. Eur Urol 1992;22:14-9.
11. Moon TD. Questionnaire survey of urologists and primary care 
physicians' diagnostic and treatment practices for prostatitis. 
Urology 1997;50:543-7.
12. Yang J, Liu L, Xie HW, Ginsberg DA. Chinese urologists' practice 
patterns of diagnosing and treating chronic prostatitis: a ques-
tionnaire survey. Urology 2008;72:548-51.
13. Krieger JN, Riley DE. Chronic prostatitis: Charlottesville to 
Seattle. J Urol 2004;172:2557-60.
14. Ku JH, Paick JS, Kim SW. Chronic prostatitis in Korea: a nation-
wide postal survey of practicing urologists in 2004. Asian J Androl 
2005;7:427-32.
15. Mehik A, Hellstrom P, Sarpola A, Lukkarinen O, Jarvelin MR. 
Fears, sexual disturbances and personality features in men with 
prostatitis: a population-based cross-sectional study in Finland. 
BJU Int 2001;88:35-8.
16. Nickel JC. The biomedical model has failed! So what is next. 
Contemp Urol 2006;1:31-9.
17. Yang CC, Lee JC, Kromm BG, Ciol MA, Berger RE. Pain sensitiza-
tion in male chronic pelvic pain syndrome: why are symptoms so 
difficult to treat? J Urol 2003;170:823-6; discussion 6-7.
18. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-pro-
static urinary reflux: an aetiological factor in abacterial prosta-
titis. Br J Urol 1982;54:729-31.
19. Persson BE, Ronquist G. Evidence for a mechanistic association 
between nonbacterial prostatitis and levels of urate and crea-
tinine in expressed prostatic secretion. J Urol 1996;155:958-60.
20. Staud R. Fibromyalgia pain: do we know the source? Curr Opin 
Rheumatol 2004;16:157-63.
21. Dadabhoy D, Clauw DJ. Fibromyalgia: progress in diagnosis and 
treatment. Curr Pain Headache Rep 2005;9:399-404.
22. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. 
Idiopathic pain disorders--pathways of vulnerability. Pain 2006; 
123:226-30.
23. Yilmaz U, Liu YW, Berger RE, Yang CC. Autonomic nervous sys-Korean J Urol 2012;53:69-77
76 Lee and Choi
tem changes in men with chronic pelvic pain syndrome. J Urol 
2007;177:2170-4.
24. McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and 
treatment of chronic abacterial prostatitis: a systematic review. 
Ann Intern Med 2000;133:367-81.
25. Nickel JC. Classification and diagnosis of prostatitis: a gold 
standard? Andrologia 2003;35:160-7.
26. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, 
Calhoun EA, Pontari MA, et al. The National Institutes of Health 
chronic prostatitis symptom index: development and validation 
of a new outcome measure. Chronic Prostatitis Collaborative 
Research Network. J Urol 1999;162:369-75.
27. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, 
Jacobsen SJ. Low agreement between previous physician diag-
nosed prostatitis and national institutes of health chronic prosta-
titis symptom index pain measures. J Urol 2004;171:279-83.
28. Schneider H, Wilbrandt K, Ludwig M, Beutel M, Weidner W. 
Prostate-related pain in patients with chronic prostatitis/chronic 
pelvic pain syndrome. BJU Int 2005;95:238-43.
29. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE Jr, 
Zeitlin S, et al. How does the pre-massage and post-massage 
2-glass test compare to the Meares-Stamey 4-glass test in men 
with chronic prostatitis/chronic pelvic pain syndrome? J Urol 
2006;176:119-24.
30. Weidner W, Anderson RU. Evaluation of acute and chronic bacte-
rial prostatitis and diagnostic management of chronic prostati-
tis/chronic pelvic pain syndrome with special reference to in-
fection/inflammation. Int J Antimicrob Agents 2008;31(Suppl 
1):S91-5.
31. Schaeffer AJ, Knauss JS, Landis JR, Propert KJ, Alexander RB, 
Litwin MS, et al. Leukocyte and bacterial counts do not correlate 
with severity of symptoms in men with chronic prostatitis: the 
National Institutes of Health Chronic Prostatitis Cohort Study. 
J Urol 2002;168:1048-53.
32. Kaplan SA, Te AE, Jacobs BZ. Urodynamic evidence of vesical 
neck obstruction in men with misdiagnosed chronic nonbacterial 
prostatitis and the therapeutic role of endoscopic incision of the 
bladder neck. J Urol 1994;152:2063-5.
33. Kaplan SA, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, 
Hendricks J, et al. Pseudodyssynergia (contraction of the external 
sphincter during voiding) misdiagnosed as chronic nonbacterial 
prostatitis and the role of biofeedback as a therapeutic option. J 
Urol 1997;157:2234-7.
34. Weidner W, Ludwig M, Brahler E, Schiefer HG. Outcome of anti-
biotic therapy with ciprofloxacin in chronic bacterial prostatitis. 
Drugs 1999;58 Suppl 2:103-6.
35. Schaeffer AJ, Anderson RU, Krieger JN, Lobel B, Naber K, 
Nakagawa M. The assessment and management of male pelvic 
pain syndrome including prostatitis. In: McConnel J, Abrams P, 
Denis L, et al., editors. Male lower urinary tract dysfunction eval-
uation and management; 6th International Consultation on New 
Developments in  Prostate Cancer and Prostate Diseases, Paris: 
Health Publications; 2006;341-85.
36. Cho IR, Keener TS, Nghiem HV, Winter T, Krieger JN. Prostate 
blood flow characteristics in the chronic prostatitis/pelvic pain 
syndrome. J Urol 2000;163:1130-3.
37. Nadler RB, Collins MM, Propert KJ, Mikolajczyk SD, Knauss JS, 
Landis JR, et al. Prostate-specific antigen test in diagnostic evalu-
ation of chronic prostatitis/chronic pelvic pain syndrome. Urology 
2006;67:337-42.
38. Pavone-Macaluso M. Chronic prostatitis syndrome: a common, 
but poorly understood condition. Part I. EAU-EBU Update Series 
2007;5:1-15.
39. Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping 
of patients with chronic prostatitis/chronic pelvic pain syndrome 
and correlation with symptom severity. Urology 2009;73:538-42; 
discussion 42-3.
40. Frazier HA, Spalding TH, Paulson DF. Total prostatoseminal 
vesiculectomy in the treatment of debilitating perineal pain. J 
Urol 1992;148:409-11.
41. Mo KI, Lee KS, Kim DG. Efficacy of combination therapy for pa-
tients with chronic prostatitis/chronic pelvic pain syndrome: a 
prospective study. Korean J Urol 2006;47:536-40.
42. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. 
Terazosin therapy for chronic prostatitis/chronic pelvic pain syn-
drome: a randomized, placebo controlled trial. J Urol 2003;169: 
592-6.
43. Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ. Alfuzosin 
treatment for chronic prostatitis/chronic pelvic pain syndrome: 
a prospective, randomized, double-blind, placebo-controlled, pi-
lot study. Urology 2003;62:425-9.
44. Evliyaoglu Y, Burgut R. Lower urinary tract symptoms, pain and 
quality of life assessment in chronic non-bacterial prostatitis pa-
tients treated with alpha-blocking agent doxazosin; versus 
placebo. Int Urol Nephrol 2002;34:351-6.
45. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic 
prostatitis/chronic pelvic pain syndrome with tamsulosin: a 
randomized double blind trial. J Urol 2004;171:1594-7.
46. Yang G, Wei Q, Li H, Yang Y, Zhang S, Dong Q. The effect of al-
pha-adrenergic antagonists in chronic prostatitis/chronic pelvic 
pain syndrome: a meta-analysis of randomized controlled trials. 
J Androl 2006;27:847-52.
47. Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, 
Pontari M, Shoskes DA, et al. Alfuzosin and symptoms of chronic 
prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008;359: 
2663-73.
48. Chuang YC, Yoshimura N, Wu M, Huang CC, Chiang PH, Tyagi 
P, et al. Intraprostatic capsaicin injection as a novel model for non-
bacterial prostatitis and effects of botulinum toxin A. Eur Urol 
2007;51:1119-27.
49. Bach D, Walker H. How important are prostaglandins in the urol-
ogy of man? Urol Int 1982;37:160-71.
50. Nickel JC, Forrest JB, Tomera K, Hernandez-Graulau J, Moon 
TD, Schaeffer AJ, et al. Pentosan polysulfate sodium therapy for 
men with chronic pelvic pain syndrome: a multicenter, random-
ized, placebo controlled study. J Urol 2005;173:1252-5.
51. Smith KB, Tripp D, Pukall C, Nickel JC. Predictors of sexual and 
relationship functioning in couples with Chronic Prostati-
tis/Chronic pelvic pain syndrome. J Sex Med 2007;4:734-44.
52. Cornel EB, van Haarst EP, Schaarsberg RW, Geels J. The effect 
of biofeedback physical therapy in men with chronic pelvic pain 
syndrome type III. Eur Urol 2005;47:607-11.
53. Anderson RU, Wise D, Sawyer T, Chan C. Integration of my-
ofascial trigger point release and paradoxical relaxation training 
treatment of chronic pelvic pain in men. J Urol 2005;174:155-60.
54. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley 
GE, Carlson BW. Management of chronic tension-type headache 
with tricyclic antidepressant medication, stress management 
therapy, and their combination: a randomized controlled trial. 
JAMA 2001;285:2208-15.
55. Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Long-term re-
sults of multimodal therapy for chronic prostatitis/chronic pelvic 
pain syndrome. J Urol 2003;169:1406-10.
56. Tugcu V, Tasci AI, Fazlioglu A, Gurbuz G, Ozbek E, Sahin S, et Korean J Urol 2012;53:69-77
Chronic Prostatitis: Approaches for Best Management 77
al. A placebo-controlled comparison of the efficiency of triple- and 
monotherapy in category III B chronic pelvic pain syndrome 
(CPPS). Eur Urol 2007;51:1113-7; discussion 8.
57. Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical pheno-
typing in chronic prostatitis/chronic pelvic pain syndrome and in-
terstitial cystitis: a management strategy for urologic chronic pel-
vic pain syndromes. Prostate Cancer Prostatic Dis 2009;12:177-83.
58. Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed 
multimodal therapy for chronic prostatitis/chronic pelvic pain 
syndrome: a prospective study using UPOINT. Urology 2010;75: 
1249-53.